Qianyi Lu

459 total citations
45 papers, 288 citations indexed

About

Qianyi Lu is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Qianyi Lu has authored 45 papers receiving a total of 288 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 19 papers in Cancer Research and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Qianyi Lu's work include HER2/EGFR in Cancer Research (14 papers), Breast Cancer Treatment Studies (12 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Qianyi Lu is often cited by papers focused on HER2/EGFR in Cancer Research (14 papers), Breast Cancer Treatment Studies (12 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Qianyi Lu collaborates with scholars based in China and Ethiopia. Qianyi Lu's co-authors include Ruoxi Hong, Fei Xu, Shusen Wang, Wen Xia, Qiufan Zheng, Kuikui Jiang, Zhongyu Yuan, Yanxia Shi, Liye Wang and Ge Qin and has published in prestigious journals such as International Journal of Molecular Sciences, Journal of Affective Disorders and European Journal of Cancer.

In The Last Decade

Qianyi Lu

36 papers receiving 286 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Qianyi Lu China 11 153 98 94 82 37 45 288
Vidyalakshmi Sethunath United States 4 137 0.9× 70 0.7× 50 0.5× 104 1.3× 55 1.5× 8 254
Lynda Corley United States 7 115 0.8× 88 0.9× 41 0.4× 122 1.5× 35 0.9× 9 231
Yumei Zhang China 8 80 0.5× 68 0.7× 63 0.7× 98 1.2× 30 0.8× 27 283
Krishna Luitel United States 6 160 1.0× 64 0.7× 44 0.5× 156 1.9× 21 0.6× 10 292
Sara Duhachek-Muggy United States 11 118 0.8× 102 1.0× 50 0.5× 171 2.1× 26 0.7× 13 326
Marion Gilormini France 5 138 0.9× 93 0.9× 83 0.9× 169 2.1× 53 1.4× 7 329
Jiawei Cao China 11 88 0.6× 81 0.8× 71 0.8× 157 1.9× 40 1.1× 20 267
Fanny Grillet France 3 175 1.1× 88 0.9× 35 0.4× 128 1.6× 17 0.5× 6 291
Seog Young Kim South Korea 7 203 1.3× 77 0.8× 33 0.4× 129 1.6× 56 1.5× 9 327
Élodie Montaudon France 8 133 0.9× 53 0.5× 82 0.9× 115 1.4× 5 0.1× 23 251

Countries citing papers authored by Qianyi Lu

Since Specialization
Citations

This map shows the geographic impact of Qianyi Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qianyi Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qianyi Lu more than expected).

Fields of papers citing papers by Qianyi Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qianyi Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qianyi Lu. The network helps show where Qianyi Lu may publish in the future.

Co-authorship network of co-authors of Qianyi Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Qianyi Lu. A scholar is included among the top collaborators of Qianyi Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qianyi Lu. Qianyi Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhou, Hanxiao, Mei Lan, Qianyi Lu, et al.. (2025). ImmuProgML: machine learning-based dissection of cancer-immune dynamics during tumor progression to improve immunotherapy. Journal of Translational Medicine. 23(1). 826–826.
2.
Lu, Qianyi, Jianwei Zhang, Limin Chen, et al.. (2024). Clinicopathological characteristics and genomic profiling of pure mucinous breast cancer. The Breast. 76. 103760–103760. 1 indexed citations
3.
4.
Song, Xiao, Longlong Dong, Qianyi Lu, et al.. (2024). The landscape of immune checkpoint-related long non-coding RNAs core regulatory circuitry reveals implications for immunoregulation and immunotherapy responses. Communications Biology. 7(1). 327–327. 5 indexed citations
5.
Li, Mei, Qianyi Lu, Jia Fu, et al.. (2023). The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer. npj Breast Cancer. 9(1). 30–30.
6.
Jiang, Kuikui, Ruoxi Hong, Qianyi Lu, et al.. (2023). Current Situation of Diagnosis and Treatment of HER2-Positive Metastatic Breast Cancer Patients in China: A Nationwide Cross-Sectional Survey of Doctors. Journal of Personalized Medicine. 13(2). 365–365.
7.
8.
Jiang, Kuikui, Ruoxi Hong, Qianyi Lu, et al.. (2023). Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-Arm, Prospective Study. Cancer Research and Treatment. 56(2). 513–521. 2 indexed citations
9.
Yan, Shuya, Shiyi Shen, Qianyi Lu, et al.. (2023). Virtual reality working memory training improves cognitive performance of acute and remitted patients with major depressive disorder. Journal of Affective Disorders. 344. 267–276. 8 indexed citations
10.
Gao, Yue, Xinyue Wang, Longlong Dong, et al.. (2023). Identifying immune checkpoint-related lncRNA biomarkers for immunotherapy response and prognosis in cancers. Scientific Data. 10(1). 663–663. 7 indexed citations
11.
Li, Jiaping, Qianyi Lu, Fei Xu, et al.. (2022). Significant response to margetuximab in Chinese HER2-positive metastatic breast cancer patient who progressed after second-line targeted therapy. Anti-Cancer Drugs. 34(7). 892–895. 2 indexed citations
12.
Hong, Ruoxi, Wen Xia, Liye Wang, et al.. (2021). Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2‐positive breast cancer: An open‐label, dose‐escalation, phase I study. Cancer Communications. 41(2). 171–182. 23 indexed citations
13.
Wang, Liye, Qianyi Lu, Kuikui Jiang, et al.. (2021). BRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review. Oncology Research and Treatment. 45(1-2). 54–61. 13 indexed citations
14.
15.
Lu, Qianyi, Fei Xu, Wen Xia, et al.. (2020). Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center. Cancer Communications. 40(5). 222–233. 15 indexed citations
16.
Li, Yi, Chengcheng Gong, Qianyi Lu, et al.. (2020). Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study. Frontiers in Oncology. 10. 271–271. 10 indexed citations
17.
Jiang, Kuikui, Wen Xia, Ruoxi Hong, et al.. (2020). Local treatment for liver oligometastases in breast cancer patients: identification of prognostic factors and exploration of appropriate treatment strategy. Translational Cancer Research. 9(2). 1225–1234. 3 indexed citations
18.
Zhang, Kai, Ruoxi Hong, Fei Xu, et al.. (2019). CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer. Cancer Letters. 447. 130–140. 35 indexed citations
19.
Lu, Qianyi, Tao Qin, Fei Xu, et al.. (2018). Clinical implication of platelet-lymphocyte ratio and PD-L1 in breast cancer patients. Translational Cancer Research. 7(3). 659–667. 1 indexed citations
20.
Qin, Tao, Qianyi Lu, Xinke Zhang, et al.. (2017). Nomogram Model of LNR Predicts Survival in Premenopausal Patients with Node-positive Luminal Breast Cancer. Anticancer Research. 37(8). 4575–4586. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vidyalakshmi Sethunath Breakdown of academic impact, for papers by Lynda Corley Breakdown of academic impact, for papers by Yumei Zhang Breakdown of academic impact, for papers by Krishna Luitel Breakdown of academic impact, for papers by Sara Duhachek-Muggy Breakdown of academic impact, for papers by Marion Gilormini Breakdown of academic impact, for papers by Jiawei Cao Breakdown of academic impact, for papers by Fanny Grillet Breakdown of academic impact, for papers by Seog Young Kim Breakdown of academic impact, for papers by Élodie Montaudon
Rankless by CCL
2026